RankingsPricing
  1. US-listed companies
  2. Ultragenyx Pharmaceutical Inc.
  3. Financials
  4. EBITDA margin (%)

Ultragenyx Pharmaceutical Inc.RARE

Market cap
$3.2B
P/E ratio
SummaryFinancials
Period EndEBITDA margin (%) YoY (%)
Dec 31, 2024-89.3-28.59%
Dec 31, 2023-125.1-27.94%
Dec 31, 2022-173.6+65.54%
Dec 31, 2021-104.9-10.58%
Dec 31, 2020-117.3-70.74%
Dec 31, 2019-400.8-41.35%
Dec 31, 2018-683.2-94.48%
Dec 31, 2017-12,370.5-93.27%
Dec 31, 2016-183,897

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)